[Express Train Episode 79] Gemvax Challenges Development of Alzheimer's New Drug

Gemvax was established on March 10, 1998, with the primary purpose of manufacturing and selling coating resins for semiconductors and displays, as well as filters. It was listed on KOSDAQ in June 2005. The company is also pursuing a bio business.

On September 15, 2014, it received approval from the Korean Ministry of Food and Drug Safety for the pancreatic cancer treatment drug Liavacs Injection (code name GV1001) as a new drug. Sales began in November 2015, starting with patient prescriptions. Phase 3 clinical trials are being conducted simultaneously at 16 major hospitals in Korea.

An Alzheimer's disease new drug is also under development. In December 2016, the Ministry of Food and Drug Safety approved the Phase 2 clinical trial plan to evaluate the efficacy and safety of GV1001 in patients with moderate to severe Alzheimer's disease. The Phase 2 clinical trial officially commenced in August 2017. In December 2019, at the Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego, USA, the Phase 2 clinical trial's primary endpoint data, the SIB score, was successfully presented.

Patent attorney Um Jeonghan of BLT Patent Law Firm reviewed Gemvax's patent and trademark application status.

Listed companies on the domestic stock market disclose patent acquisition information through the Financial Supervisory Service's electronic disclosure system. However, many stock investors tend to overlook patent disclosures.

Not only patents but also trademark registrations serve as important indicators for understanding future corporate value, as they signal the direction a listed company is heading. Some patent disclosures even act as direct triggers for stock price increases.

It is not easy for general investors to grasp the impact on companies through patent disclosures or to check trademark application statuses one by one. Asia Economy is reviewing the patent and trademark application status of listed companies together with patent attorney Um Jeonghan of BLT Patent Law Firm through the 'Express Train'.

'Express Train' is an abbreviation for a broadcast that diligently searches for stocks surging due to patents.